A significant association to decreased risk of lung cancer was observed in major allele C of rs3136038 carriers (adjusted OR=0.57, 95% CI=0.39-0.84 for CT; adjusted OR=0.75, 95% CI=0.52-1.10 for CC; adjusted OR=0.68, 95% CI=0.46-0.99 for CT+CC, compared with genotype TT), and additionally, referenced with homozygote TT, the heterozygous genotype CT showed a distinct protective effect in younger subjects (adjusted OR=0.47, 95% CI=0.26-0.86), in males (adjusted OR=0.59, 95% CI=0.37-0.93), in non-smokers (adjusted OR=0.38, 95% CI=0.20-0.72), in subjects without family history of cancer (adjusted OR=0.52, 95% CI=0.34-0.80) and in adenocarcinomas patients (adjusted OR=0.51, 95% CI=0.31-0.84).